nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABCB11—Vinblastine—head and neck cancer	0.129	0.285	CbGbCtD
Ponatinib—ABCG2—Fluorouracil—head and neck cancer	0.0661	0.146	CbGbCtD
Ponatinib—CYP2D6—Hydroxyurea—head and neck cancer	0.0587	0.13	CbGbCtD
Ponatinib—ABCG2—Docetaxel—head and neck cancer	0.0505	0.112	CbGbCtD
Ponatinib—CYP2C8—Fluorouracil—head and neck cancer	0.0352	0.0778	CbGbCtD
Ponatinib—CYP3A5—Docetaxel—head and neck cancer	0.028	0.0618	CbGbCtD
Ponatinib—ABCB1—Vinblastine—head and neck cancer	0.0221	0.0488	CbGbCtD
Ponatinib—CYP2D6—Vinblastine—head and neck cancer	0.0208	0.046	CbGbCtD
Ponatinib—ABCB1—Docetaxel—head and neck cancer	0.0182	0.0402	CbGbCtD
Ponatinib—CYP3A4—Vinblastine—head and neck cancer	0.0132	0.0292	CbGbCtD
Ponatinib—CYP3A4—Docetaxel—head and neck cancer	0.0109	0.0241	CbGbCtD
Ponatinib—FGFR3—skull—head and neck cancer	0.00879	0.0719	CbGeAlD
Ponatinib—FGFR3—cartilage tissue—head and neck cancer	0.0075	0.0613	CbGeAlD
Ponatinib—Ocular toxicity—Fluorouracil—head and neck cancer	0.00734	0.0442	CcSEcCtD
Ponatinib—Effusion—Docetaxel—head and neck cancer	0.00683	0.0412	CcSEcCtD
Ponatinib—RET—parathyroid gland—head and neck cancer	0.00592	0.0484	CbGeAlD
Ponatinib—FGFR2—skull—head and neck cancer	0.00575	0.0471	CbGeAlD
Ponatinib—Ischaemia—Vinblastine—head and neck cancer	0.00415	0.025	CcSEcCtD
Ponatinib—Non-cardiac chest pain—Docetaxel—head and neck cancer	0.00413	0.0249	CcSEcCtD
Ponatinib—Exfoliative rash—Docetaxel—head and neck cancer	0.00413	0.0249	CcSEcCtD
Ponatinib—FGFR3—hair follicle—head and neck cancer	0.00388	0.0317	CbGeAlD
Ponatinib—Myelosuppression—Vinblastine—head and neck cancer	0.00323	0.0195	CcSEcCtD
Ponatinib—Myelosuppression—Hydroxyurea—head and neck cancer	0.00294	0.0177	CcSEcCtD
Ponatinib—FGFR4—connective tissue—head and neck cancer	0.00273	0.0223	CbGeAlD
Ponatinib—FGFR2—exocrine gland—head and neck cancer	0.00266	0.0218	CbGeAlD
Ponatinib—Mucosal inflammation—Hydroxyurea—head and neck cancer	0.00249	0.015	CcSEcCtD
Ponatinib—Platelet count decreased—Hydroxyurea—head and neck cancer	0.00232	0.014	CcSEcCtD
Ponatinib—Febrile neutropenia—Hydroxyurea—head and neck cancer	0.00229	0.0138	CcSEcCtD
Ponatinib—Myelosuppression—Fluorouracil—head and neck cancer	0.00212	0.0128	CcSEcCtD
Ponatinib—FGFR2—mouth—head and neck cancer	0.00199	0.0163	CbGeAlD
Ponatinib—Atrial flutter—Docetaxel—head and neck cancer	0.00189	0.0114	CcSEcCtD
Ponatinib—LYN—connective tissue—head and neck cancer	0.00187	0.0153	CbGeAlD
Ponatinib—FGFR3—connective tissue—head and neck cancer	0.00186	0.0153	CbGeAlD
Ponatinib—KIT—exocrine gland—head and neck cancer	0.00185	0.0151	CbGeAlD
Ponatinib—BCR—parotid gland—head and neck cancer	0.00183	0.015	CbGeAlD
Ponatinib—RET—neck—head and neck cancer	0.00179	0.0147	CbGeAlD
Ponatinib—Hepatotoxicity—Hydroxyurea—head and neck cancer	0.00179	0.0108	CcSEcCtD
Ponatinib—FGFR3—epithelium—head and neck cancer	0.00177	0.0145	CbGeAlD
Ponatinib—BCR—saliva-secreting gland—head and neck cancer	0.00176	0.0144	CbGeAlD
Ponatinib—Pericardial effusion—Docetaxel—head and neck cancer	0.00175	0.0105	CcSEcCtD
Ponatinib—FGFR2—neck—head and neck cancer	0.0017	0.0139	CbGeAlD
Ponatinib—Cellulitis—Vinblastine—head and neck cancer	0.00166	0.01	CcSEcCtD
Ponatinib—Febrile neutropenia—Fluorouracil—head and neck cancer	0.00165	0.00995	CcSEcCtD
Ponatinib—FGFR4—head—head and neck cancer	0.00161	0.0132	CbGeAlD
Ponatinib—FLT3—connective tissue—head and neck cancer	0.0016	0.0131	CbGeAlD
Ponatinib—Bone pain—Vinblastine—head and neck cancer	0.00158	0.00952	CcSEcCtD
Ponatinib—Prurigo—Docetaxel—head and neck cancer	0.00155	0.00936	CcSEcCtD
Ponatinib—Myelosuppression—Docetaxel—head and neck cancer	0.00153	0.00922	CcSEcCtD
Ponatinib—Hyperuricaemia—Hydroxyurea—head and neck cancer	0.00149	0.00897	CcSEcCtD
Ponatinib—Creatinine increased—Hydroxyurea—head and neck cancer	0.00145	0.00874	CcSEcCtD
Ponatinib—Blood uric acid increased—Hydroxyurea—head and neck cancer	0.00141	0.00847	CcSEcCtD
Ponatinib—Lymphopenia—Docetaxel—head and neck cancer	0.0014	0.00845	CcSEcCtD
Ponatinib—KIT—mouth—head and neck cancer	0.00138	0.0113	CbGeAlD
Ponatinib—LYN—lymphoid tissue—head and neck cancer	0.00137	0.0112	CbGeAlD
Ponatinib—BCR—trachea—head and neck cancer	0.00135	0.0111	CbGeAlD
Ponatinib—KDR—neck—head and neck cancer	0.00133	0.0109	CbGeAlD
Ponatinib—FGFR2—saliva-secreting gland—head and neck cancer	0.00133	0.0109	CbGeAlD
Ponatinib—Skin exfoliation—Hydroxyurea—head and neck cancer	0.00132	0.00794	CcSEcCtD
Ponatinib—Mucosal inflammation—Docetaxel—head and neck cancer	0.00129	0.00781	CcSEcCtD
Ponatinib—RET—connective tissue—head and neck cancer	0.00128	0.0105	CbGeAlD
Ponatinib—Myocardial ischaemia—Fluorouracil—head and neck cancer	0.00124	0.00745	CcSEcCtD
Ponatinib—FGFR2—connective tissue—head and neck cancer	0.00122	0.00998	CbGeAlD
Ponatinib—RET—epithelium—head and neck cancer	0.00122	0.00997	CbGeAlD
Ponatinib—Febrile neutropenia—Docetaxel—head and neck cancer	0.00119	0.00718	CcSEcCtD
Ponatinib—KIT—neck—head and neck cancer	0.00118	0.00967	CbGeAlD
Ponatinib—BCR—lymphoid tissue—head and neck cancer	0.00118	0.00965	CbGeAlD
Ponatinib—Deep vein thrombosis—Docetaxel—head and neck cancer	0.00118	0.0071	CcSEcCtD
Ponatinib—FLT3—lymphoid tissue—head and neck cancer	0.00117	0.00958	CbGeAlD
Ponatinib—TEK—connective tissue—head and neck cancer	0.00117	0.00957	CbGeAlD
Ponatinib—FGFR2—epithelium—head and neck cancer	0.00116	0.00948	CbGeAlD
Ponatinib—FGFR4—lymph node—head and neck cancer	0.00113	0.00922	CbGeAlD
Ponatinib—Cerebrovascular accident—Vinblastine—head and neck cancer	0.00112	0.00676	CcSEcCtD
Ponatinib—TEK—epithelium—head and neck cancer	0.00111	0.00909	CbGeAlD
Ponatinib—LYN—head—head and neck cancer	0.0011	0.00903	CbGeAlD
Ponatinib—FGFR3—head—head and neck cancer	0.0011	0.00899	CbGeAlD
Ponatinib—Cellulitis—Fluorouracil—head and neck cancer	0.00109	0.00658	CcSEcCtD
Ponatinib—KDR—parotid gland—head and neck cancer	0.00109	0.00889	CbGeAlD
Ponatinib—LCK—trachea—head and neck cancer	0.00108	0.00882	CbGeAlD
Ponatinib—BCR—thyroid gland—head and neck cancer	0.00107	0.00876	CbGeAlD
Ponatinib—PDGFRA—connective tissue—head and neck cancer	0.00106	0.00867	CbGeAlD
Ponatinib—KDR—saliva-secreting gland—head and neck cancer	0.00104	0.00851	CbGeAlD
Ponatinib—SRC—connective tissue—head and neck cancer	0.00104	0.0085	CbGeAlD
Ponatinib—SRC—epithelium—head and neck cancer	0.000987	0.00807	CbGeAlD
Ponatinib—Face oedema—Hydroxyurea—head and neck cancer	0.000967	0.00583	CcSEcCtD
Ponatinib—KIT—parotid gland—head and neck cancer	0.000963	0.00788	CbGeAlD
Ponatinib—KDR—connective tissue—head and neck cancer	0.000956	0.00782	CbGeAlD
Ponatinib—FGFR1—thyroid gland—head and neck cancer	0.000953	0.0078	CbGeAlD
Ponatinib—BCR—head—head and neck cancer	0.000951	0.00777	CbGeAlD
Ponatinib—RET—lymphoid tissue—head and neck cancer	0.000939	0.00768	CbGeAlD
Ponatinib—Blood creatinine increased—Hydroxyurea—head and neck cancer	0.000938	0.00566	CcSEcCtD
Ponatinib—Pleural effusion—Docetaxel—head and neck cancer	0.000936	0.00564	CcSEcCtD
Ponatinib—Hepatotoxicity—Docetaxel—head and neck cancer	0.000928	0.0056	CcSEcCtD
Ponatinib—Angina pectoris—Vinblastine—head and neck cancer	0.000925	0.00557	CcSEcCtD
Ponatinib—KIT—saliva-secreting gland—head and neck cancer	0.000922	0.00754	CbGeAlD
Ponatinib—KDR—epithelium—head and neck cancer	0.000908	0.00743	CbGeAlD
Ponatinib—Breast disorder—Hydroxyurea—head and neck cancer	0.000905	0.00546	CcSEcCtD
Ponatinib—Pancytopenia—Vinblastine—head and neck cancer	0.000902	0.00543	CcSEcCtD
Ponatinib—Myocardial ischaemia—Docetaxel—head and neck cancer	0.000892	0.00538	CcSEcCtD
Ponatinib—PDGFRA—trachea—head and neck cancer	0.00089	0.00728	CbGeAlD
Ponatinib—Sepsis—Fluorouracil—head and neck cancer	0.000862	0.0052	CcSEcCtD
Ponatinib—TEK—lymphoid tissue—head and neck cancer	0.000856	0.007	CbGeAlD
Ponatinib—LCK—thyroid gland—head and neck cancer	0.000853	0.00698	CbGeAlD
Ponatinib—RET—thyroid gland—head and neck cancer	0.000853	0.00698	CbGeAlD
Ponatinib—Pancreatitis—Hydroxyurea—head and neck cancer	0.000849	0.00512	CcSEcCtD
Ponatinib—KIT—connective tissue—head and neck cancer	0.000848	0.00693	CbGeAlD
Ponatinib—ABL1—parotid gland—head and neck cancer	0.000838	0.00686	CbGeAlD
Ponatinib—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000834	0.00503	CcSEcCtD
Ponatinib—Myocardial infarction—Vinblastine—head and neck cancer	0.00083	0.005	CcSEcCtD
Ponatinib—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00083	0.005	CcSEcCtD
Ponatinib—Pancytopenia—Hydroxyurea—head and neck cancer	0.000822	0.00496	CcSEcCtD
Ponatinib—FGFR2—thyroid gland—head and neck cancer	0.000811	0.00663	CbGeAlD
Ponatinib—Neutropenia—Hydroxyurea—head and neck cancer	0.00081	0.00488	CcSEcCtD
Ponatinib—KIT—epithelium—head and neck cancer	0.000805	0.00658	CbGeAlD
Ponatinib—ABL1—saliva-secreting gland—head and neck cancer	0.000803	0.00657	CbGeAlD
Ponatinib—KDR—trachea—head and neck cancer	0.000803	0.00657	CbGeAlD
Ponatinib—TEK—thyroid gland—head and neck cancer	0.000777	0.00636	CbGeAlD
Ponatinib—PDGFRA—lymphoid tissue—head and neck cancer	0.000775	0.00634	CbGeAlD
Ponatinib—Infestation NOS—Hydroxyurea—head and neck cancer	0.000772	0.00465	CcSEcCtD
Ponatinib—Infestation—Hydroxyurea—head and neck cancer	0.000772	0.00465	CcSEcCtD
Ponatinib—Haemoglobin—Vinblastine—head and neck cancer	0.000764	0.0046	CcSEcCtD
Ponatinib—SRC—lymphoid tissue—head and neck cancer	0.00076	0.00622	CbGeAlD
Ponatinib—Haemorrhage—Vinblastine—head and neck cancer	0.00076	0.00458	CcSEcCtD
Ponatinib—Blood bilirubin increased—Docetaxel—head and neck cancer	0.000758	0.00457	CcSEcCtD
Ponatinib—RET—head—head and neck cancer	0.000757	0.00619	CbGeAlD
Ponatinib—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000757	0.00456	CcSEcCtD
Ponatinib—Hypoaesthesia—Vinblastine—head and neck cancer	0.000756	0.00456	CcSEcCtD
Ponatinib—Stomatitis—Hydroxyurea—head and neck cancer	0.000752	0.00454	CcSEcCtD
Ponatinib—Bone pain—Docetaxel—head and neck cancer	0.000748	0.00451	CcSEcCtD
Ponatinib—Cardiac failure—Fluorouracil—head and neck cancer	0.000739	0.00445	CcSEcCtD
Ponatinib—ABL1—connective tissue—head and neck cancer	0.000738	0.00603	CbGeAlD
Ponatinib—Lethargy—Fluorouracil—head and neck cancer	0.000736	0.00444	CcSEcCtD
Ponatinib—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00073	0.0044	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000721	0.00435	CcSEcCtD
Ponatinib—FGFR2—head—head and neck cancer	0.000719	0.00588	CbGeAlD
Ponatinib—Phosphatase alkaline increased—Docetaxel—head and neck cancer	0.000717	0.00432	CcSEcCtD
Ponatinib—Pulmonary embolism—Docetaxel—head and neck cancer	0.000717	0.00432	CcSEcCtD
Ponatinib—KIT—trachea—head and neck cancer	0.000712	0.00582	CbGeAlD
Ponatinib—PDGFRA—thyroid gland—head and neck cancer	0.000704	0.00576	CbGeAlD
Ponatinib—KDR—lymphoid tissue—head and neck cancer	0.000699	0.00572	CbGeAlD
Ponatinib—Haemoglobin—Hydroxyurea—head and neck cancer	0.000697	0.0042	CcSEcCtD
Ponatinib—Influenza like illness—Docetaxel—head and neck cancer	0.000696	0.0042	CcSEcCtD
Ponatinib—Haemorrhage—Hydroxyurea—head and neck cancer	0.000693	0.00418	CcSEcCtD
Ponatinib—SRC—thyroid gland—head and neck cancer	0.000691	0.00565	CbGeAlD
Ponatinib—TEK—head—head and neck cancer	0.00069	0.00564	CbGeAlD
Ponatinib—Skin exfoliation—Docetaxel—head and neck cancer	0.000684	0.00413	CcSEcCtD
Ponatinib—Fluid retention—Docetaxel—head and neck cancer	0.000681	0.0041	CcSEcCtD
Ponatinib—Neuropathy—Docetaxel—head and neck cancer	0.000673	0.00406	CcSEcCtD
Ponatinib—Alopecia—Vinblastine—head and neck cancer	0.000672	0.00405	CcSEcCtD
Ponatinib—BCR—lymph node—head and neck cancer	0.000666	0.00544	CbGeAlD
Ponatinib—FLT3—lymph node—head and neck cancer	0.000661	0.00541	CbGeAlD
Ponatinib—Dry skin—Fluorouracil—head and neck cancer	0.000661	0.00398	CcSEcCtD
Ponatinib—Nasopharyngitis—Fluorouracil—head and neck cancer	0.000645	0.00389	CcSEcCtD
Ponatinib—KDR—thyroid gland—head and neck cancer	0.000635	0.00519	CbGeAlD
Ponatinib—Angiopathy—Hydroxyurea—head and neck cancer	0.000629	0.00379	CcSEcCtD
Ponatinib—PDGFRA—head—head and neck cancer	0.000625	0.00511	CbGeAlD
Ponatinib—Sepsis—Docetaxel—head and neck cancer	0.000622	0.00375	CcSEcCtD
Ponatinib—Chills—Hydroxyurea—head and neck cancer	0.000622	0.00375	CcSEcCtD
Ponatinib—KIT—lymphoid tissue—head and neck cancer	0.00062	0.00507	CbGeAlD
Ponatinib—ABL1—trachea—head and neck cancer	0.000619	0.00507	CbGeAlD
Ponatinib—SRC—head—head and neck cancer	0.000613	0.00501	CbGeAlD
Ponatinib—Alopecia—Hydroxyurea—head and neck cancer	0.000612	0.00369	CcSEcCtD
Ponatinib—Anaemia—Vinblastine—head and neck cancer	0.000611	0.00369	CcSEcCtD
Ponatinib—Angina pectoris—Fluorouracil—head and neck cancer	0.000607	0.00366	CcSEcCtD
Ponatinib—Erythema—Hydroxyurea—head and neck cancer	0.000603	0.00364	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000598	0.00361	CcSEcCtD
Ponatinib—FGFR1—lymph node—head and neck cancer	0.000592	0.00484	CbGeAlD
Ponatinib—Leukopenia—Vinblastine—head and neck cancer	0.000592	0.00357	CcSEcCtD
Ponatinib—Pancytopenia—Fluorouracil—head and neck cancer	0.000592	0.00357	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000579	0.00349	CcSEcCtD
Ponatinib—Cardiac failure congestive—Docetaxel—head and neck cancer	0.000574	0.00346	CcSEcCtD
Ponatinib—Hypertension—Vinblastine—head and neck cancer	0.000571	0.00344	CcSEcCtD
Ponatinib—KDR—head—head and neck cancer	0.000564	0.00461	CbGeAlD
Ponatinib—KIT—thyroid gland—head and neck cancer	0.000563	0.0046	CbGeAlD
Ponatinib—Pneumonia—Fluorouracil—head and neck cancer	0.000559	0.00337	CcSEcCtD
Ponatinib—Anaemia—Hydroxyurea—head and neck cancer	0.000558	0.00336	CcSEcCtD
Ponatinib—Hot flush—Docetaxel—head and neck cancer	0.000556	0.00335	CcSEcCtD
Ponatinib—Infestation—Fluorouracil—head and neck cancer	0.000556	0.00335	CcSEcCtD
Ponatinib—Infestation NOS—Fluorouracil—head and neck cancer	0.000556	0.00335	CcSEcCtD
Ponatinib—Menopausal symptoms—Docetaxel—head and neck cancer	0.000552	0.00332	CcSEcCtD
Ponatinib—Atrial fibrillation—Docetaxel—head and neck cancer	0.000549	0.00331	CcSEcCtD
Ponatinib—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000548	0.0033	CcSEcCtD
Ponatinib—Myocardial infarction—Fluorouracil—head and neck cancer	0.000545	0.00328	CcSEcCtD
Ponatinib—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000545	0.00328	CcSEcCtD
Ponatinib—Stomatitis—Fluorouracil—head and neck cancer	0.000542	0.00327	CcSEcCtD
Ponatinib—Urinary tract infection—Fluorouracil—head and neck cancer	0.00054	0.00326	CcSEcCtD
Ponatinib—Leukopenia—Hydroxyurea—head and neck cancer	0.00054	0.00326	CcSEcCtD
Ponatinib—ABL1—lymphoid tissue—head and neck cancer	0.00054	0.00441	CbGeAlD
Ponatinib—Cardiac failure—Docetaxel—head and neck cancer	0.000533	0.00321	CcSEcCtD
Ponatinib—Lethargy—Docetaxel—head and neck cancer	0.000531	0.0032	CcSEcCtD
Ponatinib—LCK—lymph node—head and neck cancer	0.00053	0.00433	CbGeAlD
Ponatinib—RET—lymph node—head and neck cancer	0.00053	0.00433	CbGeAlD
Ponatinib—ABCG2—parotid gland—head and neck cancer	0.000529	0.00432	CbGeAlD
Ponatinib—Thrombocytopenia—Vinblastine—head and neck cancer	0.000529	0.00319	CcSEcCtD
Ponatinib—Epistaxis—Fluorouracil—head and neck cancer	0.000524	0.00316	CcSEcCtD
Ponatinib—Hyponatraemia—Docetaxel—head and neck cancer	0.000523	0.00315	CcSEcCtD
Ponatinib—Pain in extremity—Docetaxel—head and neck cancer	0.00052	0.00314	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.00052	0.00314	CcSEcCtD
Ponatinib—Migraine—Docetaxel—head and neck cancer	0.000512	0.00309	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00051	0.00307	CcSEcCtD
Ponatinib—ABCG2—saliva-secreting gland—head and neck cancer	0.000506	0.00414	CbGeAlD
Ponatinib—Haemoglobin—Fluorouracil—head and neck cancer	0.000501	0.00302	CcSEcCtD
Ponatinib—KIT—head—head and neck cancer	0.000499	0.00408	CbGeAlD
Ponatinib—Haemorrhage—Fluorouracil—head and neck cancer	0.000499	0.00301	CcSEcCtD
Ponatinib—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000496	0.00299	CcSEcCtD
Ponatinib—Oedema—Hydroxyurea—head and neck cancer	0.000492	0.00297	CcSEcCtD
Ponatinib—ABL1—thyroid gland—head and neck cancer	0.00049	0.00401	CbGeAlD
Ponatinib—Infection—Hydroxyurea—head and neck cancer	0.000489	0.00295	CcSEcCtD
Ponatinib—Paraesthesia—Vinblastine—head and neck cancer	0.000485	0.00292	CcSEcCtD
Ponatinib—Dehydration—Docetaxel—head and neck cancer	0.000484	0.00292	CcSEcCtD
Ponatinib—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000483	0.00291	CcSEcCtD
Ponatinib—TEK—lymph node—head and neck cancer	0.000483	0.00395	CbGeAlD
Ponatinib—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000482	0.00291	CcSEcCtD
Ponatinib—Skin disorder—Hydroxyurea—head and neck cancer	0.000478	0.00288	CcSEcCtD
Ponatinib—Dry skin—Docetaxel—head and neck cancer	0.000477	0.00288	CcSEcCtD
Ponatinib—Breast disorder—Docetaxel—head and neck cancer	0.00047	0.00283	CcSEcCtD
Ponatinib—Decreased appetite—Vinblastine—head and neck cancer	0.000469	0.00283	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Docetaxel—head and neck cancer	0.000469	0.00283	CcSEcCtD
Ponatinib—Nasopharyngitis—Docetaxel—head and neck cancer	0.000465	0.00281	CcSEcCtD
Ponatinib—Constipation—Vinblastine—head and neck cancer	0.000462	0.00278	CcSEcCtD
Ponatinib—Pain—Vinblastine—head and neck cancer	0.000462	0.00278	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Docetaxel—head and neck cancer	0.000459	0.00277	CcSEcCtD
Ponatinib—Arrhythmia—Fluorouracil—head and neck cancer	0.000446	0.00269	CcSEcCtD
Ponatinib—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000441	0.00266	CcSEcCtD
Ponatinib—Alopecia—Fluorouracil—head and neck cancer	0.000441	0.00266	CcSEcCtD
Ponatinib—Dyspnoea—Hydroxyurea—head and neck cancer	0.000439	0.00265	CcSEcCtD
Ponatinib—Angina pectoris—Docetaxel—head and neck cancer	0.000438	0.00264	CcSEcCtD
Ponatinib—PDGFRA—lymph node—head and neck cancer	0.000437	0.00358	CbGeAlD
Ponatinib—ABL1—head—head and neck cancer	0.000435	0.00356	CbGeAlD
Ponatinib—Erythema—Fluorouracil—head and neck cancer	0.000434	0.00262	CcSEcCtD
Ponatinib—Dyspepsia—Hydroxyurea—head and neck cancer	0.000433	0.00261	CcSEcCtD
Ponatinib—SRC—lymph node—head and neck cancer	0.000429	0.00351	CbGeAlD
Ponatinib—Decreased appetite—Hydroxyurea—head and neck cancer	0.000428	0.00258	CcSEcCtD
Ponatinib—Pancytopenia—Docetaxel—head and neck cancer	0.000427	0.00258	CcSEcCtD
Ponatinib—Abdominal pain—Vinblastine—head and neck cancer	0.000427	0.00257	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000425	0.00256	CcSEcCtD
Ponatinib—Fatigue—Hydroxyurea—head and neck cancer	0.000424	0.00256	CcSEcCtD
Ponatinib—Pain—Hydroxyurea—head and neck cancer	0.000421	0.00254	CcSEcCtD
Ponatinib—Constipation—Hydroxyurea—head and neck cancer	0.000421	0.00254	CcSEcCtD
Ponatinib—Neutropenia—Docetaxel—head and neck cancer	0.000421	0.00254	CcSEcCtD
Ponatinib—Vision blurred—Fluorouracil—head and neck cancer	0.000409	0.00247	CcSEcCtD
Ponatinib—Weight decreased—Docetaxel—head and neck cancer	0.000407	0.00245	CcSEcCtD
Ponatinib—Pneumonia—Docetaxel—head and neck cancer	0.000403	0.00243	CcSEcCtD
Ponatinib—Anaemia—Fluorouracil—head and neck cancer	0.000401	0.00242	CcSEcCtD
Ponatinib—Infestation NOS—Docetaxel—head and neck cancer	0.000401	0.00242	CcSEcCtD
Ponatinib—Infestation—Docetaxel—head and neck cancer	0.000401	0.00242	CcSEcCtD
Ponatinib—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000395	0.00238	CcSEcCtD
Ponatinib—KDR—lymph node—head and neck cancer	0.000395	0.00323	CbGeAlD
Ponatinib—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000393	0.00237	CcSEcCtD
Ponatinib—Myocardial infarction—Docetaxel—head and neck cancer	0.000393	0.00237	CcSEcCtD
Ponatinib—Stomatitis—Docetaxel—head and neck cancer	0.000391	0.00236	CcSEcCtD
Ponatinib—Jaundice—Docetaxel—head and neck cancer	0.000391	0.00236	CcSEcCtD
Ponatinib—Body temperature increased—Hydroxyurea—head and neck cancer	0.000389	0.00235	CcSEcCtD
Ponatinib—Leukopenia—Fluorouracil—head and neck cancer	0.000389	0.00234	CcSEcCtD
Ponatinib—Asthenia—Vinblastine—head and neck cancer	0.000387	0.00234	CcSEcCtD
Ponatinib—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000379	0.00229	CcSEcCtD
Ponatinib—Epistaxis—Docetaxel—head and neck cancer	0.000378	0.00228	CcSEcCtD
Ponatinib—Myalgia—Fluorouracil—head and neck cancer	0.00037	0.00223	CcSEcCtD
Ponatinib—Diarrhoea—Vinblastine—head and neck cancer	0.000369	0.00223	CcSEcCtD
Ponatinib—Haemoglobin—Docetaxel—head and neck cancer	0.000362	0.00218	CcSEcCtD
Ponatinib—Haemorrhage—Docetaxel—head and neck cancer	0.00036	0.00217	CcSEcCtD
Ponatinib—Hypoaesthesia—Docetaxel—head and neck cancer	0.000358	0.00216	CcSEcCtD
Ponatinib—Dizziness—Vinblastine—head and neck cancer	0.000357	0.00215	CcSEcCtD
Ponatinib—Oedema peripheral—Docetaxel—head and neck cancer	0.000355	0.00214	CcSEcCtD
Ponatinib—Oedema—Fluorouracil—head and neck cancer	0.000354	0.00214	CcSEcCtD
Ponatinib—Connective tissue disorder—Docetaxel—head and neck cancer	0.000354	0.00213	CcSEcCtD
Ponatinib—Asthenia—Hydroxyurea—head and neck cancer	0.000353	0.00213	CcSEcCtD
Ponatinib—Infection—Fluorouracil—head and neck cancer	0.000352	0.00212	CcSEcCtD
Ponatinib—KIT—lymph node—head and neck cancer	0.00035	0.00286	CbGeAlD
Ponatinib—Nervous system disorder—Fluorouracil—head and neck cancer	0.000348	0.0021	CcSEcCtD
Ponatinib—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000347	0.00209	CcSEcCtD
Ponatinib—Visual impairment—Docetaxel—head and neck cancer	0.000347	0.00209	CcSEcCtD
Ponatinib—Vomiting—Vinblastine—head and neck cancer	0.000343	0.00207	CcSEcCtD
Ponatinib—Headache—Vinblastine—head and neck cancer	0.000338	0.00204	CcSEcCtD
Ponatinib—Diarrhoea—Hydroxyurea—head and neck cancer	0.000337	0.00203	CcSEcCtD
Ponatinib—Eye disorder—Docetaxel—head and neck cancer	0.000336	0.00203	CcSEcCtD
Ponatinib—Cardiac disorder—Docetaxel—head and neck cancer	0.000334	0.00201	CcSEcCtD
Ponatinib—Flushing—Docetaxel—head and neck cancer	0.000334	0.00201	CcSEcCtD
Ponatinib—Angiopathy—Docetaxel—head and neck cancer	0.000327	0.00197	CcSEcCtD
Ponatinib—Dizziness—Hydroxyurea—head and neck cancer	0.000326	0.00196	CcSEcCtD
Ponatinib—Mediastinal disorder—Docetaxel—head and neck cancer	0.000324	0.00196	CcSEcCtD
Ponatinib—Chills—Docetaxel—head and neck cancer	0.000323	0.00195	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000323	0.00195	CcSEcCtD
Ponatinib—Arrhythmia—Docetaxel—head and neck cancer	0.000322	0.00194	CcSEcCtD
Ponatinib—Nausea—Vinblastine—head and neck cancer	0.000321	0.00193	CcSEcCtD
Ponatinib—Insomnia—Fluorouracil—head and neck cancer	0.000321	0.00193	CcSEcCtD
Ponatinib—Paraesthesia—Fluorouracil—head and neck cancer	0.000318	0.00192	CcSEcCtD
Ponatinib—Alopecia—Docetaxel—head and neck cancer	0.000318	0.00192	CcSEcCtD
Ponatinib—Dyspnoea—Fluorouracil—head and neck cancer	0.000316	0.0019	CcSEcCtD
Ponatinib—Mental disorder—Docetaxel—head and neck cancer	0.000315	0.0019	CcSEcCtD
Ponatinib—Erythema—Docetaxel—head and neck cancer	0.000313	0.00189	CcSEcCtD
Ponatinib—Malnutrition—Docetaxel—head and neck cancer	0.000313	0.00189	CcSEcCtD
Ponatinib—Vomiting—Hydroxyurea—head and neck cancer	0.000313	0.00189	CcSEcCtD
Ponatinib—Dyspepsia—Fluorouracil—head and neck cancer	0.000312	0.00188	CcSEcCtD
Ponatinib—Rash—Hydroxyurea—head and neck cancer	0.00031	0.00187	CcSEcCtD
Ponatinib—Dermatitis—Hydroxyurea—head and neck cancer	0.00031	0.00187	CcSEcCtD
Ponatinib—ABCG2—thyroid gland—head and neck cancer	0.000309	0.00253	CbGeAlD
Ponatinib—Headache—Hydroxyurea—head and neck cancer	0.000308	0.00186	CcSEcCtD
Ponatinib—Decreased appetite—Fluorouracil—head and neck cancer	0.000308	0.00186	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000306	0.00184	CcSEcCtD
Ponatinib—ABL1—lymph node—head and neck cancer	0.000304	0.00249	CbGeAlD
Ponatinib—Back pain—Docetaxel—head and neck cancer	0.000303	0.00183	CcSEcCtD
Ponatinib—Pain—Fluorouracil—head and neck cancer	0.000303	0.00183	CcSEcCtD
Ponatinib—Muscle spasms—Docetaxel—head and neck cancer	0.000301	0.00182	CcSEcCtD
Ponatinib—Nausea—Hydroxyurea—head and neck cancer	0.000292	0.00176	CcSEcCtD
Ponatinib—Anaemia—Docetaxel—head and neck cancer	0.00029	0.00175	CcSEcCtD
Ponatinib—Leukopenia—Docetaxel—head and neck cancer	0.000281	0.00169	CcSEcCtD
Ponatinib—Body temperature increased—Fluorouracil—head and neck cancer	0.00028	0.00169	CcSEcCtD
Ponatinib—Cough—Docetaxel—head and neck cancer	0.000273	0.00165	CcSEcCtD
Ponatinib—Hypertension—Docetaxel—head and neck cancer	0.000271	0.00163	CcSEcCtD
Ponatinib—Myalgia—Docetaxel—head and neck cancer	0.000267	0.00161	CcSEcCtD
Ponatinib—Arthralgia—Docetaxel—head and neck cancer	0.000267	0.00161	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000265	0.0016	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—head and neck cancer	0.000261	0.00157	CcSEcCtD
Ponatinib—Oedema—Docetaxel—head and neck cancer	0.000256	0.00154	CcSEcCtD
Ponatinib—Infection—Docetaxel—head and neck cancer	0.000254	0.00153	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—head and neck cancer	0.000251	0.00151	CcSEcCtD
Ponatinib—Pruritus—Fluorouracil—head and neck cancer	0.000251	0.00151	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—head and neck cancer	0.00025	0.00151	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—head and neck cancer	0.000248	0.0015	CcSEcCtD
Ponatinib—Diarrhoea—Fluorouracil—head and neck cancer	0.000242	0.00146	CcSEcCtD
Ponatinib—Dizziness—Fluorouracil—head and neck cancer	0.000234	0.00141	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000233	0.0014	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—head and neck cancer	0.000231	0.00139	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—head and neck cancer	0.00023	0.00138	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—head and neck cancer	0.000228	0.00137	CcSEcCtD
Ponatinib—Vomiting—Fluorouracil—head and neck cancer	0.000225	0.00136	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—head and neck cancer	0.000225	0.00136	CcSEcCtD
Ponatinib—Rash—Fluorouracil—head and neck cancer	0.000223	0.00135	CcSEcCtD
Ponatinib—Dermatitis—Fluorouracil—head and neck cancer	0.000223	0.00135	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—head and neck cancer	0.000222	0.00134	CcSEcCtD
Ponatinib—Headache—Fluorouracil—head and neck cancer	0.000222	0.00134	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000221	0.00133	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—head and neck cancer	0.000221	0.00133	CcSEcCtD
Ponatinib—Constipation—Docetaxel—head and neck cancer	0.000219	0.00132	CcSEcCtD
Ponatinib—Pain—Docetaxel—head and neck cancer	0.000219	0.00132	CcSEcCtD
Ponatinib—ABCB1—epithelium—head and neck cancer	0.000218	0.00178	CbGeAlD
Ponatinib—Nausea—Fluorouracil—head and neck cancer	0.000211	0.00127	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000209	0.00126	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—head and neck cancer	0.000202	0.00122	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—head and neck cancer	0.000202	0.00122	CcSEcCtD
Ponatinib—ABCB1—trachea—head and neck cancer	0.000193	0.00158	CbGeAlD
Ponatinib—ABCG2—lymph node—head and neck cancer	0.000192	0.00157	CbGeAlD
Ponatinib—CYP2D6—head—head and neck cancer	0.000188	0.00154	CbGeAlD
Ponatinib—Asthenia—Docetaxel—head and neck cancer	0.000184	0.00111	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—head and neck cancer	0.000181	0.00109	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—head and neck cancer	0.000175	0.00105	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—head and neck cancer	0.000169	0.00102	CcSEcCtD
Ponatinib—ABCB1—lymphoid tissue—head and neck cancer	0.000168	0.00137	CbGeAlD
Ponatinib—Vomiting—Docetaxel—head and neck cancer	0.000163	0.00098	CcSEcCtD
Ponatinib—Rash—Docetaxel—head and neck cancer	0.000161	0.000972	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—head and neck cancer	0.000161	0.000971	CcSEcCtD
Ponatinib—Headache—Docetaxel—head and neck cancer	0.00016	0.000966	CcSEcCtD
Ponatinib—ABCB1—thyroid gland—head and neck cancer	0.000152	0.00125	CbGeAlD
Ponatinib—Nausea—Docetaxel—head and neck cancer	0.000152	0.000916	CcSEcCtD
Ponatinib—ABCB1—head—head and neck cancer	0.000135	0.00111	CbGeAlD
Ponatinib—ABCB1—lymph node—head and neck cancer	9.47e-05	0.000774	CbGeAlD
Ponatinib—LCK—Innate Immune System—HRAS—head and neck cancer	1.08e-05	4.15e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MAPK1—head and neck cancer	1.07e-05	4.13e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EGFR—head and neck cancer	1.07e-05	4.13e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—TYMS—head and neck cancer	1.06e-05	4.09e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—head and neck cancer	1.06e-05	4.08e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—head and neck cancer	1.06e-05	4.07e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—AKT1—head and neck cancer	1.06e-05	4.07e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MAPK1—head and neck cancer	1.05e-05	4.06e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EGFR—head and neck cancer	1.05e-05	4.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MAPK3—head and neck cancer	1.05e-05	4.05e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GSTM1—head and neck cancer	1.05e-05	4.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MAPK3—head and neck cancer	1.05e-05	4.04e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—STAT3—head and neck cancer	1.05e-05	4.04e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AKT1—head and neck cancer	1.05e-05	4.03e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—STAT3—head and neck cancer	1.05e-05	4.03e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—STAT3—head and neck cancer	1.04e-05	4.02e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—head and neck cancer	1.03e-05	3.98e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—PIK3CA—head and neck cancer	1.03e-05	3.97e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—BCL2—head and neck cancer	1.03e-05	3.95e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL2—head and neck cancer	1.02e-05	3.93e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—head and neck cancer	1.02e-05	3.92e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—PIK3CA—head and neck cancer	1.01e-05	3.88e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GPX1—head and neck cancer	1e-05	3.87e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1e-05	3.86e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK3—head and neck cancer	1e-05	3.86e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK3—head and neck cancer	1e-05	3.85e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MAPK1—head and neck cancer	1e-05	3.85e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—head and neck cancer	1e-05	3.85e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MAPK1—head and neck cancer	9.97e-06	3.84e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—head and neck cancer	9.97e-06	3.84e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK3—head and neck cancer	9.97e-06	3.84e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP1A1—head and neck cancer	9.94e-06	3.83e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—PIK3CA—head and neck cancer	9.9e-06	3.81e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—PIK3CA—head and neck cancer	9.89e-06	3.81e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NAT2—head and neck cancer	9.87e-06	3.8e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—IL2—head and neck cancer	9.82e-06	3.78e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—IL2—head and neck cancer	9.64e-06	3.72e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PTEN—head and neck cancer	9.61e-06	3.7e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOTCH1—head and neck cancer	9.59e-06	3.7e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—head and neck cancer	9.57e-06	3.69e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—head and neck cancer	9.53e-06	3.67e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—MAPK1—head and neck cancer	9.53e-06	3.67e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—head and neck cancer	9.53e-06	3.67e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—head and neck cancer	9.52e-06	3.67e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MAPK1—head and neck cancer	9.51e-06	3.67e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—head and neck cancer	9.51e-06	3.67e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—head and neck cancer	9.5e-06	3.66e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—MAPK1—head and neck cancer	9.48e-06	3.65e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—head and neck cancer	9.48e-06	3.65e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PIK3CA—head and neck cancer	9.48e-06	3.65e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—head and neck cancer	9.4e-06	3.62e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PIK3CA—head and neck cancer	9.4e-06	3.62e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PIK3CA—head and neck cancer	9.37e-06	3.61e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—head and neck cancer	9.35e-06	3.6e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—head and neck cancer	9.33e-06	3.59e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PIK3CA—head and neck cancer	9.31e-06	3.59e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTEN—head and neck cancer	9.24e-06	3.56e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TYMS—head and neck cancer	9.19e-06	3.54e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—head and neck cancer	9.17e-06	3.53e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—head and neck cancer	9.16e-06	3.53e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—IL2—head and neck cancer	9.15e-06	3.53e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—head and neck cancer	9.15e-06	3.53e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PIK3CA—head and neck cancer	9.14e-06	3.52e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—IL2—head and neck cancer	9.13e-06	3.52e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—head and neck cancer	9.13e-06	3.52e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GSTM1—head and neck cancer	9.08e-06	3.5e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTEN—head and neck cancer	9.07e-06	3.5e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL2—head and neck cancer	9.04e-06	3.48e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—head and neck cancer	9e-06	3.47e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—head and neck cancer	8.92e-06	3.44e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—head and neck cancer	8.9e-06	3.43e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTEN—head and neck cancer	8.87e-06	3.42e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—head and neck cancer	8.77e-06	3.38e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—head and neck cancer	8.7e-06	3.35e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—head and neck cancer	8.69e-06	3.35e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—head and neck cancer	8.68e-06	3.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—head and neck cancer	8.67e-06	3.34e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DPYD—head and neck cancer	8.65e-06	3.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—head and neck cancer	8.65e-06	3.33e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTEN—head and neck cancer	8.61e-06	3.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—head and neck cancer	8.61e-06	3.32e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP1A1—head and neck cancer	8.61e-06	3.32e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—head and neck cancer	8.59e-06	3.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTEN—head and neck cancer	8.59e-06	3.31e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTEN—head and neck cancer	8.5e-06	3.28e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOTCH1—head and neck cancer	8.49e-06	3.27e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—head and neck cancer	8.46e-06	3.26e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—head and neck cancer	8.41e-06	3.24e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—head and neck cancer	8.35e-06	3.22e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—head and neck cancer	8.27e-06	3.19e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—head and neck cancer	8.26e-06	3.18e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—head and neck cancer	8.26e-06	3.18e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—head and neck cancer	8.25e-06	3.18e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—head and neck cancer	8.24e-06	3.17e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—head and neck cancer	8.23e-06	3.17e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—YAP1—head and neck cancer	8.21e-06	3.16e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK3—head and neck cancer	8.21e-06	3.16e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—head and neck cancer	8.2e-06	3.16e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—head and neck cancer	8.12e-06	3.13e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—head and neck cancer	8.09e-06	3.12e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—head and neck cancer	8.08e-06	3.11e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL2—head and neck cancer	8.05e-06	3.1e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—head and neck cancer	8.03e-06	3.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—head and neck cancer	8.01e-06	3.08e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TYMS—head and neck cancer	8e-06	3.08e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—head and neck cancer	7.99e-06	3.08e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—head and neck cancer	7.93e-06	3.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTM1—head and neck cancer	7.91e-06	3.05e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK3—head and neck cancer	7.89e-06	3.04e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—head and neck cancer	7.85e-06	3.02e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—head and neck cancer	7.85e-06	3.02e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MAPK1—head and neck cancer	7.81e-06	3.01e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—head and neck cancer	7.81e-06	3.01e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—head and neck cancer	7.78e-06	3e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—head and neck cancer	7.76e-06	2.99e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK3—head and neck cancer	7.75e-06	2.99e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—head and neck cancer	7.74e-06	2.98e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—head and neck cancer	7.7e-06	2.97e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—head and neck cancer	7.68e-06	2.96e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—head and neck cancer	7.68e-06	2.96e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—head and neck cancer	7.68e-06	2.96e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—head and neck cancer	7.66e-06	2.95e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—head and neck cancer	7.65e-06	2.95e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—head and neck cancer	7.64e-06	2.94e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—head and neck cancer	7.61e-06	2.93e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—head and neck cancer	7.6e-06	2.93e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—head and neck cancer	7.6e-06	2.93e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK3—head and neck cancer	7.58e-06	2.92e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—head and neck cancer	7.58e-06	2.92e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—head and neck cancer	7.58e-06	2.92e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—head and neck cancer	7.54e-06	2.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MAPK1—head and neck cancer	7.51e-06	2.89e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—head and neck cancer	7.51e-06	2.89e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1A1—head and neck cancer	7.5e-06	2.89e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—head and neck cancer	7.47e-06	2.88e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTM1—head and neck cancer	7.46e-06	2.87e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MAPK1—head and neck cancer	7.38e-06	2.84e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—head and neck cancer	7.38e-06	2.84e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK3—head and neck cancer	7.36e-06	2.84e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK3—head and neck cancer	7.34e-06	2.83e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK3—head and neck cancer	7.27e-06	2.8e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MAPK1—head and neck cancer	7.21e-06	2.78e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—head and neck cancer	7.21e-06	2.78e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—head and neck cancer	7.19e-06	2.77e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—head and neck cancer	7.14e-06	2.75e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—head and neck cancer	7.09e-06	2.73e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	7.07e-06	2.73e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—head and neck cancer	7.07e-06	2.72e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1A1—head and neck cancer	7.07e-06	2.72e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—head and neck cancer	7.02e-06	2.71e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MAPK1—head and neck cancer	7e-06	2.7e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—head and neck cancer	7e-06	2.7e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MAPK1—head and neck cancer	6.98e-06	2.69e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—head and neck cancer	6.98e-06	2.69e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—MAPK1—head and neck cancer	6.91e-06	2.66e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—head and neck cancer	6.91e-06	2.66e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—head and neck cancer	6.84e-06	2.64e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—head and neck cancer	6.78e-06	2.61e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—head and neck cancer	6.78e-06	2.61e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—head and neck cancer	6.75e-06	2.6e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—head and neck cancer	6.74e-06	2.6e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—head and neck cancer	6.72e-06	2.59e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK3—head and neck cancer	6.71e-06	2.58e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL2—head and neck cancer	6.6e-06	2.54e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—head and neck cancer	6.52e-06	2.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK3—head and neck cancer	6.47e-06	2.49e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—head and neck cancer	6.43e-06	2.48e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—head and neck cancer	6.4e-06	2.47e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MAPK1—head and neck cancer	6.38e-06	2.46e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—head and neck cancer	6.38e-06	2.46e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—head and neck cancer	6.31e-06	2.43e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—head and neck cancer	6.27e-06	2.42e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—head and neck cancer	6.27e-06	2.42e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—head and neck cancer	6.26e-06	2.41e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—head and neck cancer	6.21e-06	2.39e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—head and neck cancer	6.19e-06	2.39e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MAPK1—head and neck cancer	6.16e-06	2.37e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—head and neck cancer	6.16e-06	2.37e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—head and neck cancer	6.08e-06	2.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—head and neck cancer	6.06e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—head and neck cancer	6.03e-06	2.32e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—head and neck cancer	6e-06	2.31e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—head and neck cancer	5.92e-06	2.28e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—head and neck cancer	5.91e-06	2.28e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—head and neck cancer	5.88e-06	2.26e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—head and neck cancer	5.86e-06	2.26e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL2—head and neck cancer	5.84e-06	2.25e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—head and neck cancer	5.79e-06	2.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—head and neck cancer	5.7e-06	2.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—head and neck cancer	5.62e-06	2.17e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—head and neck cancer	5.61e-06	2.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—head and neck cancer	5.61e-06	2.16e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—head and neck cancer	5.55e-06	2.14e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—head and neck cancer	5.55e-06	2.14e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—head and neck cancer	5.54e-06	2.13e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—head and neck cancer	5.54e-06	2.13e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—head and neck cancer	5.5e-06	2.12e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—head and neck cancer	5.34e-06	2.06e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—head and neck cancer	5.32e-06	2.05e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK3—head and neck cancer	5.31e-06	2.04e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—head and neck cancer	5.23e-06	2.01e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—head and neck cancer	5.17e-06	1.99e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—head and neck cancer	5.15e-06	1.99e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—head and neck cancer	5.12e-06	1.97e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—head and neck cancer	5.12e-06	1.97e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—head and neck cancer	5.11e-06	1.97e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—head and neck cancer	5.08e-06	1.96e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MAPK1—head and neck cancer	5.05e-06	1.95e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—head and neck cancer	5.05e-06	1.94e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—head and neck cancer	4.97e-06	1.91e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—head and neck cancer	4.96e-06	1.91e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—head and neck cancer	4.95e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—head and neck cancer	4.94e-06	1.91e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—head and neck cancer	4.93e-06	1.9e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—head and neck cancer	4.92e-06	1.89e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—head and neck cancer	4.9e-06	1.89e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTM1—head and neck cancer	4.87e-06	1.88e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK3—head and neck cancer	4.7e-06	1.81e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—head and neck cancer	4.67e-06	1.8e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1A1—head and neck cancer	4.62e-06	1.78e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—head and neck cancer	4.52e-06	1.74e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MAPK1—head and neck cancer	4.47e-06	1.72e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—head and neck cancer	4.47e-06	1.72e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—head and neck cancer	4.46e-06	1.72e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—head and neck cancer	4.46e-06	1.72e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—head and neck cancer	4.38e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—head and neck cancer	4.37e-06	1.68e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—head and neck cancer	4.24e-06	1.63e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—head and neck cancer	4.2e-06	1.62e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—head and neck cancer	4.15e-06	1.6e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—head and neck cancer	4.05e-06	1.56e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—head and neck cancer	3.89e-06	1.5e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—head and neck cancer	3.88e-06	1.49e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—head and neck cancer	3.75e-06	1.45e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—head and neck cancer	3.67e-06	1.41e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—head and neck cancer	3.64e-06	1.4e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—head and neck cancer	3.59e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—head and neck cancer	3.58e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—head and neck cancer	3.17e-06	1.22e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—head and neck cancer	3.15e-06	1.21e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—head and neck cancer	2.97e-06	1.14e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—head and neck cancer	2.75e-06	1.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—head and neck cancer	2.74e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—head and neck cancer	2.59e-06	9.96e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—head and neck cancer	2.57e-06	9.91e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—head and neck cancer	2.4e-06	9.23e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—head and neck cancer	2.24e-06	8.64e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—head and neck cancer	2.11e-06	8.14e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—head and neck cancer	1.69e-06	6.51e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—head and neck cancer	1.38e-06	5.32e-06	CbGpPWpGaD
